Inclusion Body Myositis - 28 Studies Found
Completed |
: Arimoclomol in Sporadic Inclusion Body Myositis : Inclusion Body Myositis : 2008-10-08 :
|
Completed |
: Efficacy, Safety and Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis : Sporadic Inclusion Body Myositis : 2011-08-12 :
|
Completed |
: Study of Long-term Safety, Efficacy Tolerability of BYM338 in Patients With Sporadic Inclusion Body Myositis : Sporadic Inclusion Body Myositis (sIBM) : 2014-03-20 : Drug: BYM338 (Bimagrumab) |
Completed |
: Lithium in Inclusion Body Myositis (IBM) : Inclusion Body Myositis : 2009-06-08 |
Not yet recruiting |
: Study of Arimoclomol in Inclusion Body Myositis (IBM) : Inclusion Body Myositis : 2016-04-25 :
|
Completed |
: Muscle Strength and Inflammatory Response in Patients With Inclusion Body Myositis : Inclusion Body Myositis : 2009-05-11 |
Completed |
: Double-blind, Randomized, Placebo-controlled Trial of Etanercept for 12 Months in Subjects With Inclusion Body Myositis : Inclusion Body Myositis : 2008-12-04 : Drug: Etanercept 50 milligrams subcutaneously every week |
Active, not recruiting |
: An Extension Study of the Efficacy, Safety and Tolerability of BYM338 (Bimagrumab) in Patients With Sporadic Inclusion Body Myositis Who Previously Participated in the Core Study CBYM338B2203 : Sporadic Inclusion Body Myositis : 2015-07-09 :
|
Completed |
: Blood-flow Restricted Exercise in Inclusion Body Myositis : Sporadic Inclusion Body Myositis : 2014-12-10 :
|
Active, not recruiting |
: Natalizumab in Inclusion Body Myositis (IBM) : Inclusion Body Myositis (IBM) : 2013-05-31 : Drug: Natalizumab Other Name: Tysabri |